Skip to content
10-Q

Quarterly Report

Transcode Therapeutics, Inc. RNAZ

0001104659-26-062535

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 950.3K sh
Shares Diluted Q1 2026 · Mar 31, 2026 916.97K sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 172.26K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.98M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.1M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $12.84M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $17.81M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.25M
Stockholders Equity Q1 2026 · Dec 31, 2025 $10.34M
Stockholders Equity Q1 2026 · Mar 31, 2025 $10.29M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$2.02M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.38M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.49M
Total Liabilities Q1 2026 · Mar 31, 2026 $12.64M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.52M
Current Assets Q1 2026 · Mar 31, 2026 $16.75M
Current Assets Q1 2026 · Dec 31, 2025 $21.98M
Total Assets Q1 2026 · Mar 31, 2026 $157.16M
Total Assets Q1 2026 · Dec 31, 2025 $162.4M
Eps Diluted Q1 2026 · Mar 31, 2026 −$21.28
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$70.16
Eps Basic Q1 2026 · Mar 31, 2026 −$21.28
Eps Basic restated Q1 2026 · Mar 31, 2025 −$70.16
Sga Expense Q1 2026 · Mar 31, 2026 $2.22M
Sga Expense Q1 2026 · Mar 31, 2025 $951.65K
Rd Expense Q1 2026 · Mar 31, 2026 $5.11M
Rd Expense Q1 2026 · Mar 31, 2025 $2.22M
Net Income Q1 2026 · Mar 31, 2026 −$17.79M
Net Income Q1 2026 · Mar 31, 2025 −$12.09M
Operating Income Q1 2026 · Mar 31, 2026 −$17.76M
Operating Income Q1 2026 · Mar 31, 2025 −$3.17M